New Law Requires Prescribers to Offer Naloxone Under Certain Circumstances

New Law Requires Prescribers to Offer Naloxone Under Certain Circumstances

 

Effective January 1, 2019, AB 2760 (signed by then Governor Brown) requires prescribers to offer a prescription of naloxone hydrochloride (or other FDA approved drug used for the complete/partial reversal of opioid depression) to a patient when one or more of the following conditions are present:


i. The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day.
ii. An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
iii. The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder, or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.

The bill also requires that a prescriber, consistent with the existing standard of care, provide education on overdose prevention and the use of naloxone hydrochloride (or other FDA approved drug) to (i) patients receiving such prescription, and (ii) one or more persons designated by the patient, or, for a patient who is a minor, to the minor’s parent or guardian. According to the Medical Board, the prescriber will need to make the determination on the appropriate method to provide that education to the appropriate individual.

A prescriber who fails to comply with the foregoing requirements shall be referred to his or her licensing board for the imposition of administrative sanctions.

See Medical Board of California’s AB 2760 FAQs below

Downloads
MBC AB 2760 FAQs